Feedback
We would very much appreciate any thoughts you may have about OpenCME and how it could be made more useful for physicians like you.
Course Director
Michael S. Cookson, MD
Professor and Chairman
Department of Urology
University of Oklahoma Health Sciences Center
Faculty
David Jarrard, MD
Adam S. Kibel, MD
Chief, Urologic Surgery
Brigham and Women’s Hospital
Dana-Farber Cancer Institute
Elliot Carr Cutler Professor of Surgery
Harvard University School of Medicine
Boston, Massachusetts
William Lowrance, MD
Accredited by
American Urological Association
Course Description
After completing this activity, participants will be able to:
- Identify the active agents, their mechanism of action, and side effects in the management of advanced and castrate resistant prostate cancer (CRPC).
- Analyze the evidence and outcomes on the treatment of advanced and CRPC as outlined in the AUA guidelines and subsequent amendments.
- Improve diagnostic and therapeutic decision-making processes by illustrating the application of these guidelines in urological practice.
- Describe the sequencing and indications for active treatment with approved agents in the management of mCRPC
Activity Details
| Credit Types: | CME |
| Credit Amount: | 2.00 Credits |
| Release Date: | 2019-May-06 |
| Expiration Date: | 2020-May-06 |
| Estimated Time for Completion: | 2 hours |
| Registration Required: | Yes |
| Cost: | Free |
Search
Suggest a CME Activity
Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.
OpenCME for Publishers
Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.
